Skip to main content
Erschienen in: Cancer Causes & Control 11/2022

20.08.2022 | Original Paper

Physical activity from menarche-to-first pregnancy and risk of breast cancer: the California teachers study

verfasst von: Dan Lin, Ying Liu, Deirdre K. Tobias, Kathleen Sturgeon

Erschienen in: Cancer Causes & Control | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A longer menarche-to-first pregnancy window of susceptibility (WOS) is associated with increased breast cancer risk. Whether physical activity, an established preventive risk factor, during the menarche-to-first pregnancy WOS offsets breast cancer risk overall or for specific molecular subtypes is unclear.

Methods

We examined the prospective association between physical activity during the menarche-to-first pregnancy WOS and breast cancer risk in the California Teachers Study (N = 78,940). Recreational physical activity at multiple timepoints were recalled at cohort entry, and converted to metabolic equivalent of task hours per week (MET-hrs/wk). We used multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

We observed 5,157 invasive breast cancer cases over 21.6 years of follow-up. Longer menarche-to-first pregnancy WOS (≥ 20 vs. < 15 years) was associated with higher breast cancer risk (HR = 1.23, 95% CI = 1.13–1.34). Women with higher physical activity level during menarche-to-first pregnancy had lower risk of invasive breast cancer (≥ 40 vs. < 9 MET-hrs/wk: HR = 0.89, 95% CI = 0.83–0.97) and triple-negative subtype (≥ 40 vs. < 9 MET-hrs/wk: HR = 0.53, 95% CI = 0.32–0.87). No association was observed for luminal A-like and luminal B-like subtypes. Higher physical activity level was associated with lower breast cancer risk among women with moderate (15–19 years) menarche-to-first pregnancy intervals (≥ 40 vs. < 9 MET-hrs/wk: HR = 0.80, 95% CI = 0.69–0.92), but not with short (< 15 years) or long (≥ 20 years) intervals.

Conclusion

Physical activity during a WOS was associated with lower breast cancer risk in our cohort. Understanding timing of physical activity throughout the life course in relationship with breast cancer risk maybe important for cancer prevention strategies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2020) SEER cancer statistics review, 1975–2017. National Cancer Institute, Bethesda, MD Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2020) SEER cancer statistics review, 1975–2017. National Cancer Institute, Bethesda, MD
7.
Zurück zum Zitat Martinez GM (2020) Trends and patterns in Menarche in the United States: 1995 through 2013–2017. Natl Health Stat Report, pp 1–12 Martinez GM (2020) Trends and patterns in Menarche in the United States: 1995 through 2013–2017. Natl Health Stat Report, pp 1–12
8.
Zurück zum Zitat Mathews TJ, Hamilton BE (2016) Mean age of mothers is on the rise: United States, 2000–2014. NCHS Data Brief, pp 1–8 Mathews TJ, Hamilton BE (2016) Mean age of mothers is on the rise: United States, 2000–2014. NCHS Data Brief, pp 1–8
20.
Zurück zum Zitat Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109:1721–1728. https://doi.org/10.1002/cncr.22618CrossRefPubMed Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109:1721–1728. https://​doi.​org/​10.​1002/​cncr.​22618CrossRefPubMed
31.
Zurück zum Zitat Tsukamoto R, Mikami T, Miki K et al (2007) N-methyl-N-nitrosourea-induced mammary carcinogenesis is promoted by short-term treatment with estrogen and progesterone mimicking pregnancy in aged female Lewis rats. Oncol Rep 18:337–342PubMed Tsukamoto R, Mikami T, Miki K et al (2007) N-methyl-N-nitrosourea-induced mammary carcinogenesis is promoted by short-term treatment with estrogen and progesterone mimicking pregnancy in aged female Lewis rats. Oncol Rep 18:337–342PubMed
35.
Zurück zum Zitat Steindorf K, Schmidt M, Kropp S, Chang-Claude J (2003) Case-control study of physical activity and breast cancer risk among premenopausal women in Germany. Am J Epidemiol 157:121–130CrossRef Steindorf K, Schmidt M, Kropp S, Chang-Claude J (2003) Case-control study of physical activity and breast cancer risk among premenopausal women in Germany. Am J Epidemiol 157:121–130CrossRef
36.
Zurück zum Zitat Magnusson C, Roddam A, Pike M et al (2005) Body fatness and physical activity at young ages and the risk of breast cancer in premenopausal women. Br J Cancer 93:817–824CrossRef Magnusson C, Roddam A, Pike M et al (2005) Body fatness and physical activity at young ages and the risk of breast cancer in premenopausal women. Br J Cancer 93:817–824CrossRef
43.
Zurück zum Zitat Steindorf K, Ritte R, Eomois PP et al (2013) Physical activity and risk of breast cancer overall and by hormone receptor status: the European prospective investigation into cancer and nutrition. Int J Cancer 132:1667–1678CrossRef Steindorf K, Ritte R, Eomois PP et al (2013) Physical activity and risk of breast cancer overall and by hormone receptor status: the European prospective investigation into cancer and nutrition. Int J Cancer 132:1667–1678CrossRef
51.
Zurück zum Zitat Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics System. Natality on CDC WONDER Online Database. (2022) Data are from the Natality Records 2007–2020, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics System. Natality on CDC WONDER Online Database. (2022) Data are from the Natality Records 2007–2020, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program.
Metadaten
Titel
Physical activity from menarche-to-first pregnancy and risk of breast cancer: the California teachers study
verfasst von
Dan Lin
Ying Liu
Deirdre K. Tobias
Kathleen Sturgeon
Publikationsdatum
20.08.2022
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 11/2022
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-022-01617-3

Weitere Artikel der Ausgabe 11/2022

Cancer Causes & Control 11/2022 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.